BioMarin Pharmaceutical Revenue by Segment

Period Ending	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020
Voxzogo	861.39M	833.19M	795.70M	734.60M	672.30M	605.50M	534.90M	469.80M							-	-	-	-	-	-	-
Voxzogo Growth	28.13%	37.60%	48.76%	56.36%	71.99%	91.49%	125.41%	177.66%							-	-	-	-	-	-	-
Naglazyme	474.87M	484.77M	487.90M	479.50M	467.80M	444.80M	402.90M	420.30M
Naglazyme Growth	1.51%	8.99%	21.10%	14.09%	10.72%	7.67%	-8.18%	-5.30%
Palynziq	407.94M	389.54M	371.90M	354.60M	342.40M	330.70M	317.30M	304.00M
Palynziq Growth	19.14%	17.79%	17.21%	16.64%	18.68%	19.91%	20.88%	19.22%
Aldurazyme	198.44M	215.44M	197.60M	183.90M	187.60M	130.40M	132.10M	131.20M
Aldurazyme Growth	5.78%	65.21%	49.58%	40.17%	48.65%	-7.78%	-4.55%	2.18%
Brineura	184.69M	173.69M	170.30M	169.30M	164.90M	168.90M	161.70M	161.80M
Brineura Growth	12.00%	2.84%	5.32%	4.64%	2.55%	7.17%	2.86%	4.86%
Kuvan	104.03M	108.13M	109.70M	120.60M	129.30M	144.10M	166.10M	180.70M
Kuvan Growth	-19.54%	-24.96%	-33.96%	-33.26%	-34.56%	-31.93%	-24.05%	-20.57%
Royalty and Other	49.93M	46.51M	43.98M	44.48M	45.90M	47.10M	47.80M	46.80M
Royalty and Other Growth	8.78%	-1.26%	-7.99%	-4.96%	0.44%	5.61%	-4.59%	-13.17%
Roctavian	34.20M	38.40M	36.60M	26.40M	18.10M	11.70M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Roctavian Growth	88.94%	228.20%	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.